Blood pressure control: dependence on adherence

Slides:



Advertisements
Similar presentations
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
Advertisements

Management of Type 2 Diabetes New Zealand Guidelines Group.
Thiazide-Like/Calcium Channel Blocker (CCB) Agents: A Major Combination for Hypertension Management Safar M, Blacher J. Am J Cardiovasc Drugs. 2014; DOI.
Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.
Copyright © 2010 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Acute Hypertension Management Optimizing Door-to-Needle Time in Ischemic Stroke.
Current Dyslipidemia Management Guidelines Residual Risk.
Diabetes and Risk of CV Outcomes
RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL
Heart Rate, HF Admissions, and Readmissions
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
Unmet Needs in the Secondary Prevention in ACS
Medication Nonadherence in Gout
Managing Complex Hypertension: What Every Physician Should Know
Section VIII. Ambulatory BP Measurement
How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients
Resistant Hypertension
Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Early Type 2 Diabetes Mellitus: A Cardiovascular Disease
Beyond Statin Therapy.
The Vicious Cycle of Chronic Migraine How Can the Physician Help?
Hypertension Guidelines
When Would You Use Single Inhaler Triple Therapy in COPD?
Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes
What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
Engaging and Educating the Multidisciplinary Healthcare Team in HCV Care.
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
What's New in Dyslipidemia?
The future of urate-lowering strategies for gout
PCP View: ACC/AHA Guidelines: Role of Moderate Intensity Statins
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Growing Diabetes Pandemic Worldwide
PrEP.
Understanding PAD.
Initiating Pre-exposure Prophylaxis The PrEP Checklist
OTC NSAID Use in Patients With OA and CV Disease
From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP
Statins and HIV:.
Evaluating New Therapies in HF
A PCP's Guide to Dyslipidemia
CV Risk Management in T2DM: What Did We Learn from ADA 2016?
Practical Strategies to Reduce HF Hospitalizations in African American Patients.
Atrial Fibrillation.
LEADER One Year On.
Controlling High Blood Pressure
Glucose Monitoring: An Evolving Landscape
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?
Treatment-Resistant Schizophrenia
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Program Goals Disclaimers Defining Refractory Seizures.
Are We Making Progress in the Management of Huntington Disease?
Add-On Therapy to Insulin in T1DM Management
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Improving Adherence to Antiplatelet Therapy After an ACS Event
Lipid Updates From Spring 2019
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Fixed-Ratio Combination Therapy in T2DM
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Navigating the Journey
Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.
Fresh perspectives ON BASAL Insulins in diabetes care
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

Blood pressure control: dependence on adherence

Program Overview

The Importance of BP Reduction

BP Is Not Adequately Controlled

Adherence Is a Cornerstone of BP Control

High Adherence Lowers the Risk for CV Events

Adherence: The Role of PCPs

Adherence Varies According to Drug Class

Pill Burden and Adherence

FDCs

Effect of FDCs on BP

Effect of FDCs on Adherence

Effect of FDCs on Adherence (cont)

Effect of FDCs on Adherence (cont)

Other Benefits of FDCs

Healthcare Costs Associated With FDCs

Which Patients Are Best Suited to FDCs?

How Can We Improve Adherence to Antihypertensive Medications?

How Can We Improve Adherence to Antihypertensive Medications? (cont)

Summary

Abbreviations